Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6

Abstract

This study examined the mechanism of the inhibitory effect of parthenolide (PTL) on the activity of NF-κB in multiple myeloma (MM). Human multiple myeloma cell line RPMI 8226 cells were treated with or without different concentrations of PTL for various time periods, and then MTT assay was used to detect cell proliferation. Cell cycle and apoptosis were flow cytometrically detected. The level of protein ubiquitination was determined by using immunoprecipitation. Western blotting was employed to measure the level of total protein ubiquitination, the expression of IκB-α in cell plasma and the content of p65 in nucleus. The content of p65 in nucleus before and after PTL treatment was also examined with immunofluorescence. Exposure of RPMI 8226 cells to PTL attenuated the level of ubiquitinated Nemo, increased the expression of IκB-α and reduced the level of p65 in nucleus, finally leading to the decrease of the activity of NF-κB. PTL inhibited cell proliferation, induced apoptosis and blocked cell cycle. Furthermore, the levels of ubiquitinated tumor necrosis factor receptor-associated factor 6 (TRAF6) and total proteins were decreased after PTL treatment. By using Autodock software package, we predicted that PTL could bind to TRAF6 directly and tightly. Taken together, our findings suggest that PTL inhibits the activation of NF-κB signaling pathway via directly binding with TRAF6, thereby suppressing MM cell proliferation and inducing apoptosis.

Keywords

parthenolide / ubiquitination / nuclear factor-κB / tumor necrosis factor receptor-associated factor 6

References

[1] FuchsO. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets, 2013, 13(1): 16-34 PMID: 23534949

[2] KarinM, Ben-NeriahY. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol, 2000, 18: 621-663 PMID: 10837071

[3] GaspariniC, CeleghiniC, MonastaL, et al. . NF-kappaB pathways in hematological malignancies. Cell Mol Life Sci, 2014, 71(11): 2083-2102 PMID: 24419302

[4] LiZW, ChenH, CampbellRA, et al. . NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol, 2008, 15(4): 391-399 PMID: 18536579

[5] AnnunziataCM, DavisRE, DemchenkoY, et al. . Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell, 2007, 12(2): 115-130 PMCID: 2730509 PMID: 17692804

[6] KeatsJJ, FonsecaR, ChesiM, et al. . Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell, 2007, 12(2): 131-144 PMCID: 2083698 PMID: 17692805

[7] SmolinskiAT, PestkaJJ. Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. J Inflamm (Lond), 2005, 2: 6

[8] PajakB, GajkowskaB, OrzechowskiA. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol, 2008, 46(2): 129-135 PMID: 18519227

[9] HewamanaS, LinTT, JenkinsC, et al. . The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res, 2008, 14(24): 8102-8111 PMID: 19088025

[10] GuzmanML, RossiRM, KarnischkyL, et al. . The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood, 2005, 105(11): 4163-4169 PMCID: 1895029 PMID: 15687234

[11] KongF, ChenZ, LiQ, et al. . Inhibitory effects of parthenolide on the angiogenesis induced by human multiple myeloma cells and the mechanism. J Huazhong Univ Sci Technolog [Med Sci], 2008, 28(5): 525-530

[12] GhantousA, SinjabA, HercegZ, et al. . Parthenolide: from plant shoots to cancer roots. Drug Discov Today, 2013, 18(17–18): 894-905 PMID: 23688583

[13] KwokBH, KohB, NdubuisiMI, et al. . The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol, 2001, 8(8): 759-766 PMID: 11514225

[14] ZhangS, LinZN, YangCF, et al. . Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis, 2004, 25(11): 2191-2199 PMID: 15256485

[15] GuzmanML, RossiRM, NeelakantanS, et al. . An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 2007, 110(13): 4427-4435 PMCID: 2234793 PMID: 17804695

[16] FuchsO. Transcription factor NF-kappaB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol, 2010, 3(3): 98-122 PMID: 20594187

[17] ScheidereitC. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene, 2006, 25(51): 6685-6705 PMID: 17072322

[18] GautheronJ, PescatoreA, FuscoF, et al. . Identification of a new NEMO/TRAF6 interface affected in incontinentia pigmenti pathology. Hum Mol Genet, 2010, 19(16): 3138-3149 PMID: 20529958

[19] SuvannasankhaA, CreanCD, ShanmugamR, et al. . Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res, 2008, 14(6): 1814-1822 PMID: 18347184

[20] GunnEJ, WilliamsJT, HuynhDT, et al. . The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma. Leuk Lymphoma, 2011, 52(6): 1085-1097 PMID: 21417826

[21] GopalYN, ChanchornE, Van DykeMW. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther, 2009, 8(3): 552-562 PMID: 19276167

[22] NaitoA, YoshidaH, NishiokaE, et al. . TRAF6-deficient mice display hypohidrotic ectodermal dysplasia. Proc Natl Acad Sci USA, 2002, 99(13): 8766-8771 PMCID: 124373 PMID: 12060722

[23] YangWL, WangJ, ChanCH, et al. . The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science, 2009, 325(5944): 1134-1138 PMCID: 3008763 PMID: 19713527

[24] LamotheB, BesseA, CamposAD, et al. . Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem, 2007, 282(6): 4102-4112 PMCID: 3221607 PMID: 17135271